EVA Pharma

EVA Pharma, headquartered in Cairo, Egypt, focuses on developing innovative healthcare solutions across various therapeutic areas, addressing significant medical needs in low- to middle-income countries. Founded in 1997 in Cairo, Egypt, EVA Pharma specializes in the development and production of pharmaceuticals that target unmet medical needs. Under the leadership of CEO Riad Armanious, the company has established a robust presence in international markets, particularly in Africa and the Middle East. EVA Pharma’s core product offerings span a diverse range of therapeutic areas, including oncology, neuroscience, respiratory health, cardiometabolic medicine, anti-infectives, and more.

The company specializes in developing innovative healthcare solutions aimed at addressing significant unmet medical needs, particularly in low- to middle-income countries. Their product portfolio includes a mix of established medications and pioneering treatments, such as biological therapies developed through technological transfer and local manufacturing. Targeted end-users encompass patients requiring essential medicines for chronic conditions such as diabetes and HIV, as well as healthcare providers and institutions that administer these treatments. EVA Pharma distributes its products across various international markets, including regions in Africa, the Middle East, and select parts of Southeast Asia.

EVA Pharma generates revenue through a combination of direct sales and strategic partnerships, providing their products to healthcare providers, hospitals, and pharmacies. The company has established various pricing structures based on their extensive portfolio, including flagship offerings that cater specifically to high-demand therapeutic areas. Transactions typically occur via direct-to-business arrangements, with clients engaging in bulk purchases or subscription models for ongoing supply agreements. The pricing plans are designed to ensure accessibility while reflecting the advanced manufacturing and research capabilities behind their innovative solutions.

This structured approach allows EVA Pharma to maintain a steady revenue stream while addressing critical health challenges in the markets they serve.